Studium Genetics
Studium Genetics offers precision oncology diagnostics to improve early detection and prognosis for cancer patients. The company develops early diagnostic and prognostic methods in oncology using genomic and epigenomic tests. As a spin-off of the University of Bologna, it targets hospitals and clinics for adoption of its tests and clinical data workflows. Its category is B2B molecular diagnostics with collaborations with clinicians and research institutions. The focus on oral cavity cancers and precision medicine positions it to advance cancer care at scale.
Studium Genetics
Studium Genetics offers precision oncology diagnostics to improve early detection and prognosis for cancer patients. The company develops early diagnostic and prognostic methods in oncology using genomic and epigenomic tests. As a spin-off of the University of Bologna, it targets hospitals and clinics for adoption of its tests and clinical data workflows. Its category is B2B molecular diagnostics with collaborations with clinicians and research institutions. The focus on oral cavity cancers and precision medicine positions it to advance cancer care at scale.